Investment area
Seed Investments
Region
Europe
Date of investment
April 2025
Sparrow Quantum is a spin-out from a powerhouse of innovation – Professor Peter Lodahl’s research group at the Niels Bohr Institute. With 25+ years of groundbreaking research and nearly a decade of engineering expertise, we are dedicated to advancing the frontier of high-quality photon generation for quantum technologies. We specialize in light-matter interfaces – the essential building blocks for scaling optical quantum technologies. At the core of our innovation is our on-chip deterministic single-photon source, a breakthrough technology that sets industry benchmarks and is trusted by quantum technology leaders worldwide.
By delivering high-purity, high-efficiency photons, Sparrow Quantum empowers its partners and customers to push the boundaries of quantum computing and secure communication, transforming the immense potential of quantum technology into real-world innovation and impact.
Contact
Jeroen Bakker
Partner
Department: Seed Investments
Jeroen Bakker joined Seed Investments in 2018.
Jeroen currently holds several board roles and led the investment in Adcendo and Rappta Therapeutics. Prior to joining Novo, Jeroen worked at M Ventures, the corporate venture capital arm of Merck, where he focused on Seed and Series A investments across Europe, United States Israel. He was instrumental in the Artsavit Ltd investment and served on multiple boards. Jeroen held a variety of operational biotech roles in companies like Syntaxin (acquired by Ipsen), Inthera and ISD Immunotech. Prior to joining biotech, he was a Research Fellow at the La Jolla Institute for Allergy and Immunology in San Diego.
Jeroen holds a PhD in Immunology from the University of Amsterdam, an MSc in Biomedical Sciences from the Leiden University with a specialization in entrepreneurship and an BSc from the Technical University of Delft. Jeroen was chair of the Dutch Platform for Young Researchers in Nephrology and a member of REBBLS, a Danish networking organization focusing on young biotech entrepreneurs.
